BERING-CRC: BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Demographic and disease chracteristics

Date and type of BRAFV600E testing

Treatment sequence prior to and after encorafenib plus cetuximab

Evaluation of reason for treatment selection (efficacy, safety profile, quality of life, patients preference, physician's preference, comorbidities, other)

Further Overall Survival parameters

Best observed tumor response

Time to progression

Overall response rate

Duration of response

Progression-free-survival

Disease control rate

Duration of disease control

EORTC QLQ C-30 questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life C-30 questionnaires) to assess quality of life of cancer patients; comprises 30 items, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnoea, appetite loss, sleep disturbance, constipation, diarrhoea and the financial impact) scales assess symptoms. Only in case of prospective inclusion.

4-point scale: very satisfied, satisfied, dissatisfied, very dissatisfied

4-point scale: very satisfied, satisfied, dissatisfied, very dissatisfied

Number of patients with Adverse Events and maximum grade per patient, Adverse Drug Reactions, Adverse Drug Reactions grade 3/4, Serious Adverse Events, Serious Adverse Drug Reactions

From date to first treatment until date of last treatment (single compounds and whole treatment)

From date to first treatment until date of last treatment (single compounds and whole treatment)

From date to first treatment until date of last treatment (single compounds and whole treatment)

From date to first treatment until date of last treatment (single compounds and whole treatment)